Search results

613 results

Sorted by Date . Sort by Relevance

Guidance Remove Guidance filter
In development Remove In development filter
In consultation Remove In consultation filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Interventional procedures guidance Remove Interventional procedures guidance filter
Medical technologies guidance Remove Medical technologies guidance filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Social care guidelines Remove Social care guidelines filter
Quality standards Remove Quality standards filter

Bevacizumab for untreated malignant pleural mesothelioma (ID1183)

In development [GID-TA10197] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]

In development [GID-TAG321] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ovarian, fallopian tube and peritoneal cancer - rucaparib [ID1184]

In development [GID-TA10168] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

In development [GID-HST10004] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Enzalutamide for the treatment of hormone refractory prostate cancer TA316

In development [GID-TA10267] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Leukaemia (chronic lymphocytic, relapsed) - ofatumumab (maintenance) [ID732]

In development [GID-TAG482] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Vemurafenib for treating resected BRAF V600 mutation-positive melanoma ID1250

In development [GID-TA10213] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

In development [GID-HST10007] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]

In development [GID-TAG507] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab for previously treated multiple myeloma (ID1139)

In development [GID-TA10193] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]

In development [GID-TAG511] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lymphoma (mantle cell, relapsed, refractory) - lenalidomide [ID739]

In development [GID-TAG508] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Microthane implants for breast reconstruction or breast augmentation (discontinued)

In development [GID-MT267] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Cediranib for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer [ID790]

In development [GID-TA10018] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Gastroenteropancreatic neuroendocrine tumours (somatostatin, non-progressive) - lutetium-177 DOTATATE [ID857]

In development [GID-TA10033] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Biotin for treating primary and secondary progressive multiple sclerosis [ID919]

In development [GID-TA10099] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
ATA129 for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus ID1203

In development [GID-TA10204] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
SILK artery reconstruction device (discontinued)

In development [GID-MT81] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [ID1536]

In development [GID-TA10466] Expected publication date: 28 April 2021

Type

Technology appraisal guidance

Status

In development
Ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS) [ID1530]

In development [GID-TA10564] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]

In development [GID-TA10363] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]

In development [GID-TA10609] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer ID1509

In development [GID-TA10413] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Transanal total mesorectal excision for rectal cancer

In development [GID-IPG10173] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Insertion and use of implantable pulmonary artery pressure monitors in chronic heart failure

In development [GID-IPG10174] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine

In development [GID-IPG10175] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Atezolizumab monotherapy for untreated PD-L1 positive metastatic non-small-cell lung cancer [ID1678]

In development [GID-TA10587] Expected publication date: 02 June 2021

Type

Technology appraisal guidance

Status

In development
Restorative Neurostimulation to Activate the Lumbar Multifidus for chronic mechanical low back pain

In development [GID-IPG10168] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Coronary sinus stent insertion for refractory angina

In development [GID-IPG10169] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Removal, preservation and subsequent re-implantation of ovarian tissue to delay the menopause

In development [GID-IPG10170] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Pelareorep for treating metastatic or recurrent squamous cell carcinoma of the head and neck after platinum-based chemotherapy ID940

In development [GID-TA10397] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pelareorep for untreated pancreatic cancer [ID1074]

In development [GID-TA10689] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pelareorep for treating metastatic malignant melanoma after previous therapy [ID941]

In development [GID-TA10686] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pelareorep for treating relapsed or refractory multiple myeloma [ID1028]

In development [GID-TA10687] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nintedanib for treating interstitial lung disease caused by systemic sclerosis [ID1420]

In development [GID-TA10427] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [ID3775]

In development [GID-TA10636] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older (ID1195)

In development [GID-TA10435] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Omburtamab for treating relapsed neuroblastoma [ID1664]

In development [GID-TA10608] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1332]

In development [GID-TA10272] Expected publication date: 14 July 2021

Type

Technology appraisal guidance

Status

In development
Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [ID1674]

In development [GID-TA10543] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma ID1352

In development [GID-TA10319] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Luspatercept for treating anaemia caused by myelodysplastic syndromes [ID1550]

In development [GID-TA10508] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]

In development [GID-TA10623] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab for untreated PD-L1 mutation-positive non-small-cell lung cancer [ID1675]

In development [GID-TA10585] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]

In development [GID-TA10490] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]

In development [GID-TA10492] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714]

In development [GID-TA10590] Expected publication date: 19 May 2021

Type

Technology appraisal guidance

Status

In development
Liraglutide for managing obesity in people aged 12 to 17 [ID1630]

In development [GID-TA10563] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma [ID2709]

In development [GID-TA10579] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia ID1494

In development [GID-TA10424] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development